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Aimin PengAbstract
Cell division in mitosis is tightly regulated via a group of protein kinases. Activation of these mitotic kinases is
inhibited by the DNA damage checkpoint that arrests the cell cycle in interphase and prevents mitotic entry.
Interestingly, it has been shown that the DNA damage checkpoint is feedback regulated by several mitotic kinases.
These kinases are reactivated from checkpoint arrest to deactivate the checkpoint and restart cell cycle progression,
thereby allowing the cell to recover from the DNA damage checkpoint. The emerging role of mitotic kinases in the
DNA damage pathway provides important insights into cancer progression and treatment.
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DNA damage is frequently induced by radiation, geno-
toxic chemicals, and metabolic byproducts, posing enor-
mous threats on genomic integrity. Upon DNA damage,
the cell must activate the DNA damage checkpoint to
halt cell cycle progression until DNA repair is completed
[1,2]. It has been shown that the DNA damage check-
point prevents activation of cyclin-dependent kinases
(Cdks) and several other essential mitotic kinases, such as
Polo-like kinase 1 (Plk1), Aurora A and Greatwall (Gwl).
Because these mitotic kinases are inhibited by DNA dam-
age, a prevailing assumption has been that they remain in-
active until the checkpoint signal is turned off. However,
recent studies demonstrated a surprising role of these mi-
totic kinases in deactivating the checkpoint and promo-
ting cell cycle reentry in interphase, a process called
checkpoint recovery. These studies thereby suggested a re-
ciprocal regulation of the DNA damage checkpoint by mi-
totic kinases. For example, Plk1 phosphorylates several
checkpoint factors, leading to their deactivation, and has
been therefore recognized as a key player of checkpoint
recovery [3,4]. By comparison, the involvement of other
mitotic kinases in checkpoint recovery has been impli-
cated but less understood. This review will summarize re-
cent studies in the field, and discuss how these findingsCorrespondence: Aimin.Peng@UNMC.edu
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reproduction in any medium, provided the ormay impact our understanding of cancer progression
and therapy.
Activation of the DNA damage checkpoint
Various forms of DNA damage can be induced in cells
by endogenous or exogenous agents. An important part
of the cellular response to DNA damage is to stop cell
cycle progression when DNA damage is sensed. This
mechanism, termed the DNA damage checkpoint, is be-
lieved to facilitate DNA repair and prevent genomic
instability [1]. The essential role of the checkpoint is
highlighted by the fact that genetic mutations of the
pathway are often implicated in human diseases. In par-
ticular, DNA damage checkpoint genes, including ATM,
TP53, BRCA1, CHEK2, NBS1, MRE11, were found fre-
quently mutated in familial cancer patients with various
penetrance, indicating a critical tumor suppression role
of the pathway [2,5].
Extensive research efforts were dedicated to revealing
the molecular network of the DNA damage checkpoint.
It is now well-established that a key event following
DNA damage is activation of ATM and ATR, two phos-
phatidylinositol 3-kinase-related kinases (PIKKs) that
are widely regarded as sensor kinases. Upon activation,
ATM and ATR phosphorylate a large number of sub-
strate proteins to regulate various downstream pathways,
including DNA repair, checkpoint activation, and cell
death [6]. Activation of the DNA damage checkpoint is
mediated by two checkpoint kinases, Chk1 and Chk2.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and ATM, and in turn phosphorylate substrates such as
Cdc25 and p53 to control cell cycle progression [1].
Cdc25 functions as an essential activator of Cdks by
dephosphorylating Cdks at inhibitory sites [7]; p53 acti-
vates transcription of p21 which then inhibits Cdk acti-
vation [1]. Thus, the current model of the DNA damage
checkpoint is centered at inhibitory regulation of Cdks,
such as Cdk1/Cyclin B, the principal mitotic kinase whose
inhibition upon activation of the G2/M DNA damage
checkpoint would effectively block mitotic entry.
In addition to Cdk1, there are a number of other ki-
nases whose activities also oscillate during the cell cycle
and peak in mitosis. Many of these kinases are believed
to play important roles in mitotic entry, progression, and
exit. For example, polo-like kinase 1 (Plk1) is a well-
studied mitotic kinase whose inactivation leads to multi-
ple mitotic defects and cell death. Plk1 contains a kinase
domain and a characteristic polo-box domain that is in-
volved in determination of subcellular localization and
substrate selectivity. Upon activation, Plk1 phosphory-
lates a wide range of substrates, including Cdc25, Wee1,
Emi2, Bora, etc., involved in various aspects of mitosis
[3,4]. Interestingly, recent studies indicated that Plk1 is
activated by another well-characterized mitotic kinase
named Aurora A, which phosphorylates Plk1 at its T-loop
activating site [8,9]. Aurora A phosphorylates and regu-
lates numerous mitotic substrates, whereas the function of
Aurora A is mediated by various activators/co-factors, in-
cluding Bora, Tpx2, Ajuba, Hef1, etc. [3,10]. Aurora A
belongs to the Aurora family of kinases along with Aurora
B and C. Despite similarities in structure and substrate
recognition, Aurora B and Aurora A exhibit distinct pat-
terns of subcellular localization and protein interaction
[11,12]. Moreover, recent studies revealed that mitotic
entry and maintenance are dependent on a relatively less-
studied kinase named Greatwall (Gwl, as known as Mastl:
microtubule-associated serine/threonine kinase like). Gwl
phosphorylates Ensa and Arpp-19, two related factors
that, upon phosphorylation, specifically bind and inhibit
a protein phosphatase complex named PP2A/B55δ. In-
hibition of this phosphatase complex prevents it from
dephosphorylating Cdk1 substrates, and is therefore a pre-
requisite for mitotic entry and maintenance [13-16]. Rea-
ders are referred to several excellent reviews for detailed
functions and regulatory mechanisms of these mitotic
kinases [3,4,10-17].
Interestingly, emerging evidence indicated that many
of these non-Cdk mitotic kinases are also targeted by
the G2/M DNA damage checkpoint, presumably to re-
inforce the G2 arrest resulted from Cdk1 inhibition. It
has been shown that Plk1 activation is inhibited by DNA
damage [18,19]. Importantly, expression of a constitu-
tively active form of Plk1 overrides the G2/M DNAdamage checkpoint, indicating an essential involvement
of Plk1 inhibition in checkpoint activation [18]. It is still
unclear how DNA damage leads to Plk1 inhibition dur-
ing G2/M transition. PP2A-mediated dephosphorylation
has been suggested as a potent mechanism of Plk1 de-
activation because Plk1 activation is triggered by phos-
phorylation at its activating site. In mitosis, some studies
[20,21], although not others [22], found that DNA dam-
age leads to Plk1 dephosphorylation. Interestingly, Aur-
ora A is also inhibited by DNA damage in a manner that
is independent of Cdk inhibition [23]. Aurora A inhi-
bition by DNA damage requires Chk1-dependent signa-
ling, and is somehow dependent on phosphorylation of
Ser-342 of Aurora A. Overexpression of wild-type or
Ser-342 to Ala-mutant Aurora A in DNA damage-
treated cells led to checkpoint bypass and mitotic entry,
suggesting a functional significance of Aurora A inhib-
ition in the DNA damage checkpoint [23]. Finally, our
recent study in Xenopus egg extracts discovered inhib-
ition of Gwl kinase by DNA damage: pre-activated Gwl
is more efficiently deactivated in extracts supplemented
with DNA damage compared to the control interphase
extract; such inhibition is sensitive to caffeine, an inhibi-
tor of ATM/ATR [24]. Collectively, these recent studies
suggest a “multi-brake” model of the G2/M DNA dam-
age checkpoint, in which the checkpoint targets not only
Cdk1, but also several other mitotic kinases, and like
that of Cdk1, inhibition of these non-Cdk kinases is es-
sential for activation and maintenance of the DNA dam-
age checkpoint (Figure 1).
Deactivation of the DNA damage checkpoint—checkpoint
recovery
Activation of the DNA damage checkpoint allows the
cell to successfully repair DNA damage. Upon comple-
tion of DNA repair, the cell deactivates the checkpoint
and resumes cell cycle progression, which process is
termed checkpoint recovery. Compared to activation of
the DNA damage checkpoint, checkpoint recovery is
much less understood, and was only recently appreciated
as an active and regulated process [25,26]. Giving that
the checkpoint is activated largely through protein phos-
phorylation and kinase cascades, the emerging role of
protein phosphatases in checkpoint recovery is not sur-
prising [27]. In particular, PP2Cδ, also known as Wip1
(wild-type p53-induced phosphatase 1) has been shown
to antagonize activation of multiple components of the
stress and DNA damage response pathways. Expression
of Wip1 is enhanced hours after DNA damage in a p53-
dependent manner; Wip1 then dephosphorylates and de-
activates ATM, γ-H2AX, Chk1, Chk2 and other DNA
damage checkpoint factors, thereby promoting checkpoint
recovery [28,29]. Interestingly, several mitotic kinases,









Figure 1 A multi-brake model of the G2/M DNA damage
checkpoint. Activation of the DNA damage checkpoint and
maintenance of cell cycle arrest require not only inhibition of Cdk1,
but also independent targeting of Plk1, Aurora A and Gwl. Detailed
mechanisms through which the DNA damage checkpoint
suppresses Plk1, Aurora A and Gwl kinases remain to be clarified
(as denoted by the question mark).
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The involvement of these kinases in checkpoint recovery
is further discussed below:
Plk1. The role of Plk1 as an essential regulator of
checkpoint recovery from DNA damage-induced G2 ar-
rest was first reported by van Vugt et al. [30,31]. Inter-
estingly, this study showed that down-regulation of Plk1,
which did not block mitotic entry in unperturbed cell
cycle, significantly delayed mitotic reentry after DNA
damage [30]. Such a differential requirement of Plk1 for
checkpoint recovery and for normal cell cycle progres-
sion suggests specific functions of Plk1 in checkpoint
recovery. The checkpoint recovery deficiency in Plk1-
suppressed cells can be rescued by depletion of Wee1, a
tyrosine kinase that inhibits Cdk activation, thereby
suggesting Wee1 as a crucial downstream factor of Plk1
in promoting checkpoint recovery [30]. More recently,
the role of Plk1 in checkpoint recovery was further re-
vealed through characterization of Claspin as a direct
target of Plk1 during the recovery process. Claspin
functions as a mediator protein that allows ATR to
phosphorylate and activate Chk1 [32]. Yoo et al. firstdiscovered in Xenopus egg extracts that Plk1 phospho-
rylates Claspin after prolonged interphase arrest in
aphidicolin-treated extracts, leading to release of Claspin
from chromatin and checkpoint inactivation [33]. While
this study was conducted within the context of check-
point adaptation, a term specifically referring to cell
recovery despite presence of DNA damage, from replica-
tion checkpoint, this role of Plk1 in checkpoint deactiva-
tion through Claspin regulation may also account for
DNA damage checkpoint recovery. Indeed, a similar
mode of regulation was then reported in human cells
with independent studies from several laboratories con-
firming Plk1-dependent phosphorylation of Claspin as a
crucial event of checkpoint recovery. Interestingly, these
elegant studies showed that Plk1-dependent phosphory-
lation directs Claspin to Skp/Cullin/F-box-β-Transducin
repeat containing protein (SCF-βTrCP)-mediated ubi-
quitination and proteolysis [34-36]. More recently, it has
been shown that Plk1 phosphorylates Chk2 and 53BP1,
a checkpoint protein that mediates ATM-dependent
phosphorylation of downstream factors. These phospho-
rylation events disrupt the function of 53BP1 and Chk2
in checkpoint signaling [37]. Collectively, the studies sum-
marized above revealed an essential role of Plk1 in check-
point recovery by directly targeting multiple DNA damage
checkpoint factors, and thereby allowing checkpoint-
deactivation and cell cycle reentry.
Aurora A. It has been shown that activation of Plk1 is
dependent on Aurora A during both a normal mitosis
and checkpoint recovery [8,9]. When complexed to a co-
factor named Bora, Aurora A phosphorylates Plk1 at
Thr-210, the T-loop activation site of Plk1. Both Aurora
A and Bora are required for checkpoint recovery and
mitotic reentry after DNA damage, and not so surpris-
ingly, the requirement of Aurora A for checkpoint reco-
very is overcome by expression of a constitutively active
form of Plk1, indicating that Aurora A promotes check-
point recovery largely through Plk1 [8].
Cdk. Cdks are central regulators of the cell cycle.
Cdk1, in particular, is essential for the cell to enter mi-
tosis, and must be inhibited during activation of the G2
DNA damage checkpoint. The notion that Cdk1 activa-
tion is suppressed by the DNA damage checkpoint
seemingly contradicts with any possible role of Cdk1 in
the DNA damage response. However, Cdk1 has been
shown to function in various aspects of DNA repair and
the DNA damage checkpoint [38,39]. A crucial role of
Cdk1 in DNA repair, especially homologous recombin-
ation, has been shown in yeast and human cells [40-45].
Cdk1 activity was found necessary for proper DNA end
resection, a critical step of homologous recombination;
and consistently, a number of studies revealed that Cdk1-
dependent phosphorylation of CtIP and other repair pro-
teins mediates their functions in DNA end resection
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yeast that Cdk1 is required for double strand break-
induced checkpoint activation [40]. This function of Cdk1
is likely to be conserved in human cells [50], and may be
attributed to both Cdk1-mediated DNA end resection that
is required for ATR activation [51], and direct phosphoryl-
ation of Chk1 that is required for efficient activation of
Chk1 [52,53]. The role of Cdk1 in regulating DNA repair
and initiating checkpoint activation may reflect its mo-
lecular actions before DNA damage occurs or at least be-
fore the checkpoint is fully established. However, Cdk1
has also been shown to function in checkpoint recovery, a
process that is, ironically, required for reactivation of
Cdk1 and mitotic reentry. In fission yeast, Cdk1 phos-
phorylates Crb2, the homolog of Rad9 in budding yeast
and 53BP1/Mdc1/Brca1 in human; this phosphorylation
occurs during the late stage of the DNA damage response
and is required for cell cycle reentry after DNA damage
[54]. Conserved to Cdk1-dependent phosphorylation of
Crb2 in fission yeast, human 53BP1 is phosphorylated by
Cdk1 in mitosis. This phosphorylation by Cdk1 then
primes for further phosphorylation of 53BP1 by Plk1, and
eventually leading to deactivation of 53BP1 in the check-
point signaling pathway [37]. Similarly, Mdc1 has also
been suggested as a substrate of Cdk1, and Cdk1-de-
pendent regulation disrupts Mdc1 and γ-H2AX inter-
action, presumably to avoid checkpoint activation during
mitosis [55]. As these studies were focused on mitotic
regulation of the DNA damage checkpoint, additional evi-
dence is required to link these Cdk1-mediated phosphor-
ylation events with checkpoint recovery in interphase.
Interestingly, a different mode of mechanism by which
Cdk activity promotes checkpoint recovery has been re-
vealed [56,57]. Alvarez-Fernandez et al. showed that re-
covery from the G2 DNA damage checkpoint requires
Cdk-dependent phosphorylation and activation of FoxM1,
which at G2 controls transcription of Cyclin A, Cyclin B,
Plk1 and other cell cycle genes [56]. These authors sug-
gested an interesting model in which Cdk activity is pre-
served at a low level during the DNA damage response,
and such residual Cdk activity is required for maintaining
the competency of the cell for checkpoint recovery. Al-
though the authors found no apparent physiological im-
portance of this residual activity for an unperturbed cell
cycle, its inhibition led to failure of checkpoint recovery.
The Cdk activity was shown to be dependent on Cyclin A
rather than Cyclin B [56]. Clearly, further characterization
of this Cdk activity, especially how it is protected from the
DNA damage checkpoint, and its detailed molecular
actions, will substantially improve our understanding
of checkpoint recovery.
Gwl. First identified in Drosophila, Greatwall (Gwl)
has been extensively characterized in Xenopus and human
cells as an essential mitotic kinase [13,16]. Interestingly,we recently discovered an involvement of Gwl in check-
point recovery [24,58,59]. Depletion of Gwl from Xenopus
egg extracts impaired checkpoint recovery, as judged by
persistent activation of checkpoint proteins and delayed
reactivation of Cdk1 after removal of DNA damage. Con-
versely, overexpression of wild-type, but not kinase-dead,
Gwl suppressed checkpoint signaling in response to DNA
damage [24]. While these results established Gwl as an es-
sential regulator of checkpoint recovery, it remains un-
clear how Gwl functions in the recovery process. For
example, does Gwl regulate the DNA damage checkpoint
through Ensa and Arpp-19, currently the only known sub-
strates of Gwl, or alternatively, could Gwl target other fac-
tors involved in the DNA damage checkpoint pathway?
Future perspectives
Though checkpoint recovery is still understood to a
much less extent compared to checkpoint activation, a
great deal of knowledge about this process has been
learned through revealing the involvement of mitotic
kinases. However, with the emerging role of multiple mi-
totic kinases in checkpoint recovery arise many intri-
guing questions, in particular, their regulation, mutual
relationship, and implications to cancer. Continued re-
search efforts are required to address these key ques-
tions in the near future.
How are mitotic kinases reactivated during checkpoint
recovery
Current understanding of the role of mitotic kinases in
checkpoint recovery can be summarized as: 1) these ki-
nases are inhibited by the DNA damage checkpoint to
allow checkpoint activation and prevent mitosis; and
2) reactivation of these kinases deactivates checkpoint
signaling and leads to cell recovery. These two lines of
evidence are seemingly contradictory and disconnected
by a major gap-in-knowledge: How do these kinases re-
activate from checkpoint arrest? In principle, reactiva-
tion of these kinases before checkpoint deactivation may
suggest two possibilities: 1) an internal timer-like me-
chanism evokes activation of these kinases from check-
point arrest even with unrepaired DNA damage and
persistent checkpoint signaling; 2) the checkpoint does
not fully abrogate activation of these mitotic kinases,
which maintain a residual level of activities as a result of
both activating and suppressing signals. During check-
point recovery, the suppressing signal reduces owing to
progression of DNA repair, and thereby shifting the ba-
lance toward further activation of these kinases (Figure 2).
The core of the timer model lies in that checkpoint re-
covery can be committed spontaneously after prolonged
checkpoint arrest with or without completion of DNA re-
pair, which notion was possibly reflected in previous stu-




















Figure 2 A balance model of checkpoint recovery. The choice between checkpoint activation (A) and recovery (B) is controlled by reciprocal
regulation of checkpoint factors and mitotic kinases. Establishment of the DNA damage checkpoint inhibits full-activation of mitotic kinases,
which however, retain residual levels of activities. Checkpoint recovery can be initiated as the balance between the checkpoint machinery and
mitotic kinases shifts: reduced checkpoint signaling leads to increased activities of mitotic kinases, which then further suppress checkpoint











Figure 3 Checkpoint recovery allows cancer cells to bypass the
DNA damage checkpoint during cancer progression and
therapy. Therefore, checkpoint recovery is of great interests to
better understanding tumorigenesis, improving cancer diagnosis,
and developing future therapeutics.
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covery without completion of DNA repair is consistent
with the checkpoint adaptation phenomenon characterized
in yeast, Xenopus, and mammalian cells [25,26]. In particu-
lar, the G2/M DNA damage checkpoint in mammalian
cells has been described as “imperfect” for allowing cell cy-
cle reentry without completion of DNA repair [62,63].
The balance model is supported by the recent ob-
servation of residual activities of mitotic kinases during
checkpoint arrest. In theory these activities can be quickly
elevated with the weakening of checkpoint signals, leading
to further deactivation of checkpoint signals, and eventu-
ally mitotic reentry (Figure 2). An elegant example of such
theory was presented in the previous study that discovered
residual Cdk activity during DNA damage-induced G2 ar-
rest and demonstrated an essential role of this activity in
conferring cell competency for checkpoint recovery [56].
Moreover, our previous study in Xenopus egg extracts also
noted a residual activity of Gwl kinase in interphase egg
extracts treated with DNA damage [24].
Given the important role of Plk1 and other mitotic ki-
nases in checkpoint recovery, it is plausible that reactiva-
tion of these kinases from checkpoint arrest is a critical
point of checkpoint recovery. The timer model and bal-
ance model can both account for reactivation of these
kinases as such process is likely to involve coordinated
actions of distinct mechanisms. Future delineation of
these molecular mechanisms should substantially ad-
vance our understanding of how the cell transits from
the state of checkpoint activation to recovery.
How is checkpoint recovery related to cancer progression
and treatment
The critical role of the DNA damage checkpoint path-
way in cancer progression has been firmly established,owing to the fact that germline mutations of check-
point genes lead to genomic instability syndromes char-
acterized by developmental defects, aging phenotypes,
and particularly, predisposition to cancers. For example,
ataxia-telangiectasia (AT) is an autosomal recessive dis-
order resulting from loss of ATM, and associated with
lymphoid malignancy along with other phenotypes [6].
Similarly, a variety of disorders have been attributed to
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Nijmegen breakage syndrome, Mre11 in AT-like disorder,
ATR in Seckel syndrome, Chk2 and p53 in Li-Fraumeni
syndrome [64]. Notably, most cancer patients are born
with an intact DNA damage pathway, and the checkpoint
is often activated during early stages of cancer progression
as an anti-cancer barrier [65-67]. Thus, to reveal how the
DNA damage checkpoint fails in cancer cells to prevent
tumorigenesis will yield general understanding of cancer
progression. In principle, there are two ways by which
cancer cells may escape the damage response during can-
cer progression and therapy: through genetic mutations
that cripple the checkpoint pathway, or by hijacking cellu-
lar mechanisms that would naturally deactivate the check-
point. Thus, it is not surprising that known factors of the
checkpoint recovery pathway, including Plk1, Aurora A
and Wip1, were found to be upregulated in cancers in cor-
relation with more aggressiveness and poor prognosis.
The oncogenic potential of these factors was also strongly
supported by functional studies in established cancer cell
lines and mouse models (reviewed in [3,12,28,68,69]). The
role of mitotic kinases in checkpoint recovery further sug-
gests that upregulation of these kinases in cancer cells not
only directly promotes cell cycle progression, but also al-
lows cells to bypass the checkpoint-mediated tumor sup-
pression (Figure 3). This knowledge sheds new lights on
the oncogenic nature of these kinases, and is of potential
value for cancer prevention and diagnosis.
Checkpoint recovery allows cell survival and continued
proliferation after DNA damage, and could therefore yield
great implications to cancer therapy, especially radiothe-
rapy and chemotherapy using DNA damaging agents.
These forms of cancer treatments exploit the toxicity of
DNA damage to eliminate tumor cells. Importantly, DNA
repair and checkpoint recovery attenuate the killing effect
of the treatment and lead to undesired outcomes, and
upregulation of the checkpoint recovery mechanism in
cancer cells may cause chemoresistance and tumor re-
currence (Figure 3). Excitingly, clinical and pre-clinical
studies have suggested Plk1, Aurora A and Wip1 as pro-
mising drug targets to confer enhanced cancer therapy,
consistent with the role of these kinases in checkpoint re-
covery, mitosis, and other processes. There are currently
more than a dozen chemical inhibitors of these factors
that are being evaluated in cancer clinical trials [3,12,28].
Future delineation of checkpoint recovery, especially the
role of mitotic kinases as essential regulators, will be a key
to understanding how tumor cells escape radio- or che-
motherapy and relapse, thus building the foundation to
enhance cancer therapy.
Conclusion
A critical aspect of the cellular response to DNA damage
is to halt cell cycle progression through the checkpointmechanism. It has been well-established that activation
of the DNA damage checkpoint at G2 leads to inhibition
of Cdk1 kinase, the principal mitotic kinase. Interes-
tingly, recent studies in various systems have made a
convincing case that Cdk1 is not the only mitotic kinase
targeted by the DNA damage checkpoint. Other mitotic
kinases, including Plk1, Aurora A, and Gwl, have also
been shown to be inhibited by DNA damage as neces-
sary mechanisms to activate the checkpoint and pre-
vent mitotic entry. These lines of evidence thus suggest a
“multi-brake” model of checkpoint activation. Conversely,
as shown in many recent studies, these mitotic kinases
also antagonize checkpoint signaling, and thereby pro-
mote checkpoint deactivation and cell cycle reentry, a
process termed “checkpoint recovery”. Importantly, the
checkpoint recovery process is tightly associated with
both cancer progression and treatment. Upregulation of
factors involved in checkpoint recovery has been com-
monly detected in cancer cells, in correlation with ag-
gressive cancer progression and poor treatment outcome.
Further delineation of the mutual relationship between
mitotic kinases and the DNA damage checkpoint may
yield valuable information to improve cancer prevention,
diagnosis and treatment in the near future.
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